Home · Technology · Sep 23 archive
Anthropic says its biology lab has already found something big
Confirmed
In Short: Despite these uncertainties, Anthropic's move into wet lab biology represents a significant shift in the company's strategy, aligning with its broader ambition to tackle complex biological challenges.
Anthropic has announced that its AI model, Claude, has discovered a new molecular machine in the DNA of bacteriophages, viruses that infect bacteria.
The company's head of life sciences, Eric Kauderer-Abrams, confirmed the existence of Anthropic's wet lab during a Reuters interview.
According to Anthropic, the find represents a significant step in its efforts to unlock treatments for rare diseases.
Kauderer-Abrams emphasized the importance of human oversight and involvement for safety, despite the company's ambitions to automate biology work.
Anthropic's CEO, Dario Amodei, has a personal stake in the project, driven by the potential to address diseases neglected by the pharmaceutical industry.
Amodei has acknowledged the potential dangers of advanced AI and the need for safety measures, while not ruling out fully automated biology labs in the future.
What this adds
The exact diseases Anthropic is targeting and its progress remain unclear.
What's confirmed
- Anthropic Says Claude Found Something Big in DNA.
What's still developing
- "We believe that to do biology, the final test is still and will be for a while in real lab work," he said.
- The move represents a small step toward Anthropic’s enormous ambition to tackle diseases that it thinks the pharmaceutical industry is neglecting — and to do so before staff and the public lose faith that AI justifies erasing jobs and possibly human life, one of the people said.
- Like other biotech companies, Anthropic is embracing physical automation, said the two people, who spoke on condition of anonymity.
- In the past two weeks, some of its researchers warned that AI could lead to human extinction, and Anthropic said it found examples where its systems could have been used toward biological weapons development, which met some skepticism, opens new tab.
- At the same time, Anthropic is preparing to go public in a potentially $2 trillion IPO to raise more money for such AI development.
- Anthropic staked out its intention to start running drug programs, at a San Francisco event in June.
- On stage there, Kauderer-Abrams said Anthropic would do preclinical work in areas that traditional companies did not find attractive financially.
- Now, Anthropic is bulking up its in-house lab efforts for speed and for firsthand experience in biology, though it outsources work when efficient, Kauderer-Abrams told Reuters.
- Anthropic has looked to hire a leader who could ramp up procurement and other operations, it said in a recent LinkedIn job post.
- Life sciences already represents one of Anthropic’s biggest investment areas by headcount and resources, Kauderer-Abrams said.
- The precise diseases Anthropic is addressing and its progress remain unclear.
- Sept 18 - Anthropic has quietly set up a laboratory to do physical biology work as it pushes its artificial-intelligence ambitions into the world of drug science.